FDA pushes back decision on Zogenix epilepsy drug

FDA pushes back decision on Zogenix epilepsy drug

Source: 
BioPharma Dive
snippet: 

The Food and Drug Administration pushed back its target date for a decision on Zogenix's epilepsy medicine Fintepla by three months to June 25, citing the need to review new information submitted by the company.